[1] Wang Y D, Zhao C Y, Yin H Z. Primary hepatic amyloidosis: a mini literature review and five cases report[J].Ann Hepatol,2012,11(5):721-727.
[2] Zhao L, Ren G, Guo J, et al. The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement[J].Ann Med,2022,54(1):1226-1232.
[3] Ye L, Shi H, Wu H M, et al. Primarily isolated hepatic involvement of amyloidosis: a case report and overview[J].Medicine (Baltimore),2016,95(52):e5645.
[4] Martens P, Nevens F. Budd-Chiari syndrome[J]. United European Gastroenterology Journal, 2015,3(6):489-500.
[5] Rössle M. Interventional treatment of Budd-Chiari syndrome[J].Diagnostics (Basel),2023,13(8):1458.
[6] Porrello G, Mamone G, Miraglia R. Budd-Chiari syndrome imaging diagnosis: state of the art and future perspectives[J].Diagnostics (Basel), 2023,13(13):2256.
[7] Zhou P, Ren J, Han X, et al. Initial imaging analysis of Budd-Chiari syndrome in Henan province of China: most cases have combined inferior vena cava and hepatic veins involvement[J].PLoS One, 2014,9(1):e85135.
[8] Zhang J, Liu C, Zheng Z, et al. Budd-Chiari syndrome: the "inferior vena cava reverse-flow" sign and "jet-blood" sign on CT and MRI[J].Eur J Radiol,2020,132:109288.
[9] Khan F, Armstrong M J, Mehrzad H, et al. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J].Aliment Pharmacol Ther,2019,49(7):840-863.
[10] Liu K, Ding Y, Xu Y, et al. AL amyloidosis with primary presentation of multiple serous cavity effusion and severe cholestasis: a case report and review of literature[J].BMC Gastroenterol, 2022,22(1):128.
[11] Tiryaki T O, Yönal Hindilerden i, Yegen G, et al. Budd-Chiari syndrome: an unusual complication of AL amyloidosis[J].Turk J Haematol,2020,37(2):130-131.
[12] Cançado G G L, Faria L C, Osório F M F, et al. Budd Chiari syndrome associated with AL amyloidosis: a coagulation paradox[J].Amyloid,2018,25(1):70-71. |
